Su466 LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN A REAL-WORLD IBD COHORT
Gastroenterology（2021）
Key words
biosimilar sb5,originator adalimumab,long-term,real-world
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined